Advertisement
/ 18 []

EURAMOS 1


EURAMOS. EURAMOS is the European and American Osteosarcoma Study Group. The study was founded in 2001.Children\'s Oncology GroupCooperative Osteosarcoma Study GroupEuropean Osteosarcoma IntergroupScandinavian Sarcoma Group. EURAMOS. Established Oct 2001Aim to improve survival from OSObjecti

Download Presentation

EURAMOS 1

An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use only and may not be sold or licensed nor shared on other sites. SlideServe reserves the right to change this policy at anytime.While downloading, If for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.











- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -




Presentation Transcript


Euramos 1 l.jpg

EURAMOS 1

A randomised trial of the European and American Osteosarcoma Study Group to optimize treatment strategies for resectable osteosarcoma based on histological response to pre-operative chemotherapy

Jeremy Whelan for the EURAMOS 1 Trial Management Group, 4th November 2006


Euramos l.jpg

EURAMOS

  • EURAMOS is the European and American Osteosarcoma Study Group. The study was founded in 2001.

    • Children’s Oncology Group

    • Cooperative Osteosarcoma Study Group

    • European Osteosarcoma Intergroup

    • Scandinavian Sarcoma Group


Euramos3 l.jpg

EURAMOS

  • Established Oct 2001

  • Aim

    • to improve survival from OS

  • Objectives

    • to carry out large international randomised trials

    • to facilitate biological research

    • to seek new therapeutic approaches

    • to develop common understanding and methodologies for staging, pathology etc.


Euramos 14 l.jpg

EURAMOS 1

  • Co-sponsored

    • MRC in Europe

    • COG for North America

  • Co-ordinating Data Centre

    • MRC Clinical Trials Unit


Trial design l.jpg

Trial Design


Trial design6 l.jpg

Trial Design

  • Key registration criteria

    • High grade OS of extremity or axial skeleton

    • Resectable disease

    • Fit for treatment


Trial design7 l.jpg

Trial Design

  • Key randomisation criteria

    • Adequate pre-operative chemotherapy

    • Macroscopically complete resection of primary tumour

    • Complete removal of all metastases or complete removal planned and feasible

    • Histological response assessment


Trial design8 l.jpg

Trial Design

  • Primary Objectives

    • Addition of IE to post-op MAP chemotherapy improves EFS for poor responders

    • Addition of ifn to post-op MAP chemotherapy improves EFS for good responders


Trial design9 l.jpg

Trial Design

  • Secondary Objectives

    • Additional treatment improves OS, short and long term toxicity and quality of life

    • Additional treatment improves EFS in localised disease

    • Investigate biological and clinical correlated to histological response and outcome

    • International cooperation in trials

    • Examine outcome of the entire cohort of patients


Trial design additional studies l.jpg

Trial Design- additional studies

  • Quality of Life

  • Biology Studies


Euramos participants l.jpg

EURAMOS participants


Progress open and recruiting l.jpg

Progress: open and recruiting


Progress almost ready l.jpg

Progress: almost ready

  • Austria

  • Finland


Progress requests to join l.jpg

Progress: requests to join

  • Czech Republic

  • Ireland

  • Poland

  • Israel


Accrual l.jpg

Accrual

302 Registered


Accrual16 l.jpg

Accrual

  • 302 Registered


Accrual17 l.jpg

Accrual

123 Randomised


Euramos 118 l.jpg

EURAMOS 1

  • Chief Investigators

    • Mark Bernstein (TMG Chair)

    • Neyssa Marina (COG)

    • Stephan Bielack (COSS)

    • Jeremy Whelan (EOI)

    • Sigbjorn Smeland (SSG)

  • Website

    • www.euramos.org